AHF Research is dedicated to discovering better treatments and improving quality of life for people living with HIV.
AHF Research is uniquely positioned to design and implement research studies with the aim to support AHF’s commitment to high-quality HIV and STI prevention, testing, treatment, and advocacy. AHF Research has years of experience and expertise with clinical trials, device validation, comorbidity reduction, program evaluation, laboratory management, regulatory management, data collection and analysis, quality control, quality assurance, and academic publishing.
AHF Research Grant Fund
AHF Research seeks to support innovative research through collaborations and/or providing seed funding. AHF’s extensive clinical database and worldwide healthcare services offer unique opportunities for researchers interested in HIV/STI prevention, testing, treatment, and advocacy.
AHF Research Studies
AHF Research has over a decade of research experience in the HIV/STI fields. Listed below are a sampling of research publications over that time-period:
- Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
- Psychiatric Symptoms in Patients Receiving Dolutegravir.
- Comparing mail-in self-collected specimens sent via United States Postal Service versus clinic-collected specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in extra-genital sites.
- Comparative Evaluation of 2 Nucleic Acid Amplification Tests for the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae at Extragenital Sites.
- Advocacy Coalition for Safer Sex in the Adult Film Industry: The Case of Los Angeles County’s Measure B.
- Were We Prepared for PrEP? Five Years of Implementation.
- A Smartphone Application to Reduce Time-to-Notification of Sexually Transmitted Infections.
AHF Research Leadership
Otto Yang, MD is a distinguished physician-scientist who has served as AHF’s Scientific Director since 2012.
Dr. Yang received his medical degree from Brown University Medical School in 1990. He subsequently completed a residency in Internal Medicine at Bellevue Hospital/New York University from 1990 to 1993 during the height of the AIDS epidemic, and then trained in infectious diseases at Massachusetts General Hospital/Harvard Medical School, leading to board certification in infectious diseases. During his fellowship training, he spent time running the HIV clinic at the only maximum-security prison in Massachusetts, where he was the sole provider of HIV care.
Dr. Yang served as faculty at Harvard from 1997 to 1999, and moved to University of California Los Angeles in 1999, where he reached the rank of full professor in 2008. He has been the Associate Chief of Infectious Diseases since 2010, and plays an active role in mentoring students, faculty, and junior faculty.
As a scientist, Dr. Yang has been studying the basic disease processes of HIV infection since 1994. He has an active research laboratory that focuses on the immune response against HIV using tools in molecular immunology and virology, which has been funded by National Institutes of Health funding since 1995. Dr. Yang is an author on over 110 peer-reviewed scientific publications, has authored books and book chapters, and submitted several patent applications for his work. Over the past decade, he has served as an expert consultant to National Institutes of Health for reviewing grants and sitting on advisory panels for HIV vaccine research, as well as being an editorial board member for Journal of Virology and PLoS One and reviewing scientific articles for numerous scientific journals.
Dr. Yang’s most recently ongoing research projects include studying how the virus mutates to escape the immune response, the role of the viral Nef protein in disease, and harnessing nanotechnologies to design vaccines and novel therapeutics for HIV.